Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival

• المؤلفون الرئيسيون: Hind A. Alkhatabi (مؤلف), Samir F. Zohny (مؤلف), Mohammed Razeeth Shait Mohammed (مؤلف), Hani Choudhry (مؤلف), Mohd Rehan (مؤلف), Aamir Ahmad (مؤلف), Farid Ahmed (مؤلف), Mohammad Imran Khan (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2022-02-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid leukemia (AML) or elderly patients non-eligible for chemotherapy. However, acquiring resistance to ven...